title: [Five cases of severe radiation pneumonitis after chemoradiotherapy for esophageal cancer].
abstract: Chemoradiotherapy( CRT) for esophageal cancer is a useful modality for both locally advanced and resectable cases. Among adverse events related to CRT, radiation pneumonitis( RP) requires special attention because it has been shown to be occasionally associated with a worse acute prognosis. We report 5 cases of severe RP after CRT. All patients were male, and their mean age was 72 years (range: 66-76 years). The clinical stage of esophageal cancer was I in 1 case, II in 2 cases, and IVa in 2 cases. The mean total radiation dose was 51.8 Gy (range: 43.4-61.4). Initial symptoms and first abnormal findings were a high fever in 4 cases and elevated serum C-reactive protein( CRP) levels in 1 case. No patients presented with respiratory symptoms, including dyspnea and coughing, as initial symptoms. All cases were diagnosed as RP by chest computed tomography examination, an average of 6.8 days after the completion of RT. Four patients required intensive care and were put on ventilator support. All patients received steroid pulse therapy. Two patients recovered from RP; however, 3 died( 1 attributable to multi-organ failure and 2 to respiratory failure). It is important to consider RP caused by CRT when patients present with high fever or elevated CRP levels after the completion of RT for esophageal cancer.
authors.affiliation: Dept. of Surgical Oncology, Osaka City University Graduate School of Medicine.
authors.forename: Katsunobu
authors.initials: K
authors.lastname: Sakurai
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kubo
authors.forename: Masatsune
authors.initials: M
authors.lastname: Shibutani
authors.forename: Sadaaki
authors.initials: S
authors.lastname: Yamazoe
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagahara
authors.forename: Takahiro
authors.initials: T
authors.lastname: Toyokawa
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Amano
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Muguruma
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohtani
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yashiro
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Maeda
authors.forename: Masaichi
authors.initials: M
authors.lastname: Ohira
authors.forename: Kosei
authors.initials: K
authors.lastname: Hirakawa
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D059248:Chemoradiotherapy; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017564:Radiation Pneumonitis / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents